Key Highlights
- Ilissa Larimore joins Solarea Bio as Chief Commercial Officer (CCO).
- Over 20 years of experience in consumer health, wellness, and practitioner engagement.
- Will oversee sales, marketing, partnerships, and industry collaborations.
- Focus on advancing new products, including Bondia™ synbiotic for menopausal women.
Source: PR Newswire
Notable Quotes
- “We are thrilled to welcome Ilissa Larimore to the Solarea Bio team. Her extensive experience in commercial strategy and her passion for leveraging nutrition and medical foods to improve human health make her an invaluable addition to our leadership team.” — Dr. Gerardo V. Toledo, CEO and co-founder at Solarea Bio
- “I am honored and excited to join Solarea Bio at such a pivotal time,” said Ilissa Larimore. “The company’s groundbreaking work to develop novel products based on plant-derived microbes, supported by rigorous clinical development aligns perfectly with my passion for commercializing medical foods that focus on the practitioner-patient relationship to improve health outcomes.” — Ilissa Larimore, Chief Commercial Officer at Solarea Bio
SoHC's Take
Ilissa Larimore’s appointment as Chief Commercial Officer is a strategic move by Solarea Bio to strengthen its commercial capabilities as it prepares to launch its Journa™ consumer health brand and Bondia™ synbiotic product. With her extensive background in consumer health and personalized wellness, Ilissa is well-positioned to drive the company’s commercial strategy and expand its market impact. Her experience with nutritional interventions and medical foods will be invaluable as Solarea Bio aims to address unmet needs in disease management, starting with bone loss in menopausal women and targeting conditions like rheumatoid arthritis. This appointment underscores Solarea Bio’s commitment to leveraging innovative technology to improve health outcomes and highlights the company’s potential for significant growth in the biotechnology sector.
